NASDAQ · KRYS

Krystal Biotech, Inc.

$335.19 +$7.69 (+2.35%) 1D After hours
Session Pulse Overnight session 2 mentions on Tue · 1 bullish / 0 bearish tags No new SEC filings since Mon close its sector ranked 6/11 this week Full pulse →
Charting by TradingView

Key Metrics

$9.65B
Market cap
42.90×
P/E · TTM
$417.30M
Revenue · TTM
$225.03M
Net income
EPS · TTM $7.53
Dividend yield —
Free cash flow $237.38M
Beta · 1Y 0.77
EBITDA · TTM $184.64M
Gross margin —

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 21
    A material event was filed (Form 8-K).

    8-K - Krystal Biotech, Inc. (0001711279) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$9.65B
Enterprise value—
Shares outstanding29.5M
52-wk range$130.50 – $382.54
Avg volume · 20D266.9K
Net cash —
Book value / share$42.74
IndustryBiological Products, (No Diagnostic Substances)
ExchangeNASDAQ
About Krystal Biotech, Inc.
IPO dateSep 20, 2017
Employees295

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E42.90
P/S23.14
P/FCF40.67
EV/EBITDA—
EV/Sales—
Graham №$85.12

Profitability

Gross —
Operating 42.8%
Net 53.9%
FCF 56.9%
ROE / ROIC 20.2% · 42.8%

Financial Health

Current ratio9.46
Quick ratio9.06
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$911.94M

Cash Flow · TTM

Operating CF $250.28M
Capex −$12.90M
Free cash flow $237.38M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

49.8
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$85.12 vs $335.19
Trades 3.9× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings